1. ADHERENCE TO ORAL ANTICANCER THERAPIES IN A CLINICAL CANCER CENTRE. (November 2019) Authors: De Gregori, J.; Coudert, B.; Desmoulins, I.; Favier, L.; Isambert, N.; Zanetta, S.; Ghiringhelli, F.; Vincent, J.; Ladoire, S.; Hennequin, A.; Lagrange, A.; Hervieu, A.; Di Martino, C.; Gallet, M.; Quipourt, V.; Lefevre, L.Bengrine; Schmitt, A. Journal: Journal of geriatric oncology Issue: Volume 10(2019)Supplement 1 Page Start: S86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Successful switch to dabrafenib after vemurafenib‐induced toxic epidermal necrolysis. (15th March 2015) Authors: Jeudy, G.; Dalac‐Rat, S.; Bonniaud, B.; Hervieu, A.; Petrella, T.; Collet, E.; Vabres, P. Journal: British journal of dermatology Issue: Volume 172:Number 5(2015:May) Page Start: 1454 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Successful switch to dabrafenib after vemurafenib‐induced toxic epidermal necrolysis. (1st May 2015) Authors: Jeudy, G.; Dalac‐Rat, S.; Bonniaud, B.; Hervieu, A.; Petrella, T.; Collet, E.; Vabres, P. Journal: British journal of dermatology Issue: Volume 172:Number 5(2015:May) Page Start: 1454 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). (October 2022) Authors: Besse, B.; Springfeld, C.; Baik, C.; Hervieu, A.; Solomon, B.; Moreno, V.; Bazhenova, L.; Goto, K.; Kim, Y.C.; Lu, S.; Sun, M.; Trone, D.; Thamake, S.; Cho, B.C.; de Langen, A.; Popat, S.; Wolf, J.; Moro-Sibilot, D.; Fang, J.; Drilon, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗